熱門資訊> 正文

吉利德认为第二季度每股收益受到IPR & D费用的打击

2025-07-12 06:23

Gilead Sciences (NASDAQ:GILD) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process research and development (IPR&D) charges, leading to a ~($0.04) reduction in GAAP and non-GAAP EPS.
The company said ~$40M of the charge is related to its partnership with Kymera Therapeutics (KYMR) announced in June to develop cancer drugs, while the other ~$21M is attributed to other collaborations and partnerships.
Non-GAAP EPS consensus for the quarter is $1.97, while GAAP EPS consensus is $1.48.
Gilead reports earnings on Aug. 1.

More on Gilead Sciences

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Arcus says Gilead-partnered cancer drug won FDA orphan status
Gilead in pact to speed up access to new HIV therapy in low-income nations

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。